Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT and Immunotherapy Prior to TORS for HPV+ OPSCC
NCT03618134Phase 2Terminated
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Oct 2018
- Primary completion
- Jun 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab in oropharyngeal squamous cell carcinoma (OPSCC), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoints: Incidence of adverse events, Progression-free survival up to 2 years and 1 more. Started Oct 2018; status: terminated.
02
Drugs
durvalumab
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT03618134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03618134.